倾向妊娠期巨细胞病毒血清学筛查预防先天性感染的成本效果分析
该研究从法国国家医疗保险系统角度,基于100万孕妇假设人群,评估早孕期原发感染后产前检测先天性巨细胞病毒(cCMV)的成本效果。人群筛查使检出率从15%升至94%,伐昔洛韦二级预防使严重感染新生儿减少58%,总成本仅增3.5%。
要点
- 人群血清学筛查可提高cCMV检出率,但增加高额费用与组织成本
- 伐昔洛韦二级预防显著降低严重感染新生儿比例
- 需权衡筛查成本与临床获益以制定临床指南
核心结论
- 基于人群的CMV血清学筛查可大幅提高cCMV检出率,但 monetary 和组织成本高;伐昔洛韦二级预防以较小额外成本显著减少严重感染新生儿。
研究设计与样本
- 成本效果研究,基于已发表概率估计及合理范围,假设100万孕妇人群,从法国国家医疗保险系统角度分析。
主要发现
- 将检测策略转为人群筛查使cCMV检出率从15%提高到94%,并增加 monetary 和组织成本。
- 伐昔洛韦二级预防对母胎CMV传播和新生儿临床结局有显著效果,严重感染新生儿减少58%,总成本增加3.5%。
- 考虑女性决策(羊膜穿刺 uptake 和严重病例终止妊娠)未影响成本效果结果。
关键数值与推荐
- 人群筛查策略下cCMV检出率从15%升至94%。
- 伐昔洛韦二级预防使严重感染新生儿减少58%,总成本增加3.5%。
临床怎么用
- 研究结果可为制定cCMV感染识别和宫内治疗临床指南提供参考。
局限性
- 研究基于假设人群和已发表概率估计,非实际临床队列数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of prenatal detection of congenital cytomegalovirus (cCMV) following maternal primary infection in the first trimester within standard pregnancy follow-up or involving population-based screening (serological testing at 7 and 12 weeks of gestation), with or without secondary prevention (valaciclovir) in maternal CMV primary infection. DESIGN: Cost-effectiveness study from the perspective of the French national health insurance system. SETTING: Cost-effectiveness based on previously published probability estimates and associated plausible ranges hypothetical population of 1,000,000 pregnant women. POPULATION: Hypothetical population of 1,000,000 pregnant women. METHODS: Cost-effectiveness of detecting fetal cCMV in terms of the total direct medical costs involved and associated expected outcomes. MAIN OUTCOME MEASURES: Detection rates and clinical outcomes at birth. RESULTS: Moving to a population-based approach for targeting fetal CMV infections would generate high monetary and organizational costs while increasing detection rates from 15% to 94%. This resource allocation would help implementing horizontal equity according to which individuals with similar medical needs should be treated equally. Secondary prevention with valaciclovir had a significant effect on maternal-fetal CMV transmission and clinical outcomes in newborns, with a 58% decrease of severely infected newborns for a 3.5% additional total costs. Accounting for women decision-making (amniocentesis uptake and termination of pregnancy in severe cases) did not impact the cost-effectiveness results. CONCLUSIONS: These findings could fuel thinking on the opportunity of developing clinical guidelines to rule identification of cCMV infection and administration of in-utero treatment. These findings could fuel the development of clinical guidelines on the identification of congenital CMV infection and the administration of treatment in utero. TWEETABLE ABSTRACT: CMV serological screening followed by valaciclovir prevention may prevent 58% to 71% of severe cCMV cases for 38 € per pregnancy.
引用
- Seror V, Leruez-Ville M, Ӧzek A, et al. Leaning towards Cytomegalovirus serological screening in pregnancy to prevent congenital infection: a cost-effectiveness perspective. BJOG. 2021. PMID: 34651405. doi:10.1111/1471-0528.16966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。